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the identified proteins were the heat shock proteins HSP60 
and HSP70 that were significantly downregulated both in 
recurrences- and metastases-derived cell lines but not in pri-
mary tumor-derived cell lines. Moreover, we identified sig-
nificant upregulation of the annexin V, calreticulin and the 
inorganic pyrophosphatase (PPA1) exclusively in the metas-
tases-derived cell lines. As these upregulated proteins could 
potentially become novel biomarkers of metastasis, we have 
compared their abundance in primary tumor LSCC N(0) 
cases, primary tumor LSCC N(+) cases as well as in LSCC 
metastases N(+). Our results show an intense increase of 
cytoplasmic PPA1 abundance in the N(+) (p = 0.000042) 
compared to the N(0) group. In summary, we show a group 
of proteins deregulated in recurrences and metastases of 
LSCC. Moreover, we suggest the PPA1 protein as a poten-
tial new biomarker for metastasis in this cancer.
Keywords LSCC · Laryngeal cancer · PPA1 · 
Metastasis · Biomarker
Abstract Relapse and metastasis are the main causes of 
unfavorable outcome in head and neck cancers. Whereas, 
understanding of the molecular background of these pro-
cesses is far from being complete. Therefore, in this study 
we aimed to identify potential biomarker candidates of 
relapse and metastasis in laryngeal squamous cell carci-
noma (LSCC) by combining the 2D electrophoresis based 
protein screen and immunohistochemical analysis of candi-
date proteins. We screened three groups of LSCC cell lines 
derived from primary tumors, recurrent tumors and metas-
tases and identified seven proteins that differed significantly 
in relative abundance between the analyzed groups. Among 
Handling Editor: P. R. Jungblut.
M. Bodnar and M. Luczak contributed equally to this manuscript.
Electronic supplementary material The online version of this 
article (doi:10.1007/s00726-016-2201-8) contains supplementary 
material, which is available to authorized users.
 * Maciej Giefing 
 giefingm@man.poznan.pl
1 Department of Clinical Pathomorphology, Collegium 
Medicum in Bydgoszcz, Nicolaus Copernicus University 
in Torun, Bydgoszcz, Poland
2 Institute of Bioorganic Chemistry, Polish Academy 
of Sciences, Poznan, Poland
3 Department of Cancer Genetics, Institute of Human Genetics, 
Polish Academy of Sciences, Poznan, Poland
4 Department of Otorhinolaryngology, Head and Neck Surgery, 
Turku University Hospital and University of Turku, Turku, 
Finland
5 Department of Medical Biochemistry, Turku University 
Hospital and University of Turku, Turku, Finland
6 Institute of Chemical Technology and Engineering, Poznan 
University of Technology, Poznan, Poland
7 Chair of Oncologic Pathology and Epidemiology,  
Poznan University of Medical Sciences and Greater Poland 
Cancer Center, Poznan, Poland
8 Department of Audiology and Phoniatrics, Poznan University 
of Medical Sciences, Poznan, Poland
9 Department of Hematology and Bone Marrow 
Transplantation, Poznan University of Medical Sciences, 
Poznan, Poland
10 Department of Otolaryngology and Laryngeal Oncology, 
Poznan University of Medical Sciences, Poznan, Poland
1470 M. Bodnar et al.
1 3
Introduction
Laryngeal squamous cell carcinoma (LSCC) is one of 
the most common cancers of the head and neck in males 
in European countries. Although the age standardized 
incidence for men decreased in the last two decades 
still 8.8 per 100,000 are diagnosed yearly with the dis-
ease (Ferlay et al. 2013). LSCC patients’ survival rates 
are unsatisfactory low with the 5-year survival of 67 % 
(De Angelis et al. 2014) and decrease dramatically when 
the tumor is diagnosed in advanced stage, relapses or 
metastasizes.
Several proteins have been reported so far to corre-
late with progression and/or metastases of LSCC tumors 
including the up-regulation of matrix metalloproteinases 
(MMPs) (Görögh et al. 2006; Uloza et al. 2011; Bodnar 
et al. 2014); cyclin D1 (CCND1) (Zhang et al. 2013; Jar-
muz-Szymczak et al. 2013) or the downregulation of tumor 
suppressive proteins TSLC1 (Lu et al. 2012) or PCDH17 
(Haruki et al. 2010; Giefing et al. 2011). Moreover, Cai 
et al. (2012) investigated transcription regulation networks 
to identify regulators for lymph node metastasis in LSCC 
and showed SP1 and c-MYC transcription factors, which 
may affect LSCC metastasis by promoting the epithelialm-
esenchymal transition (Cai et al. 2012).
Despite, recent advances in identifying proteins related 
to the metastatic potential of LSCC the understanding of 
the molecular background of the metastatic process is far 
from being complete. This necessitates the identification of 
proteins associated with recurrence or metastasis that could 
possibly become biomarkers of metastasis and targets of 
novel personalized therapies.
In this study, by comparing the 2D proteome profiles 
of LSCC cell lines derived from primary tumors (n = 11), 
recurrent tumors (n = 9) and metastases (n = 6), we iden-
tified seven proteins that were significantly differentially 
represented in these groups. Moreover, we compared the 
abundance of the best protein marker candidates by immu-
nohistochemistry in primary LSCC tumor sections (20 N(0) 
tumors, 20 N(+) tumors and 20 lymph node SCC metasta-
ses) and validated the findings from cell lines.
Material and methods
LSCC cell lines and culture conditions
Twenty-six cell lines established at the University of Turku, 
Finland, from patients diagnosed with LSCC were ana-
lyzed. The characteristics of the original material taken 
to establish the cell lines are shown in the supplementary 
(Table S1). Most of the cell lines were characterized in ear-
lier studies (Jarmuz et al. 2002, 2005; Järvinen et al. 2006; 
Giefing et al. 2008). We have confirmed the stability of the 
used cell lines in earlier experiments by karyotyping on dif-
ferent passages. Moreover, array-CGH profiles as well as 
mRNA expression profiles of these cell lines present typi-
cal LSCC characteristics including copy number changes 
of specific genomic regions and transcriptional deregula-
tion of tumor related genes (Kostrzewska-Poczekaj et al.; 
Giefing et al. 2011; Jarmuz et al. 2002, 2005; Järvinen et al. 
2006). The cells were grown in 25-cm2 flasks in Dulbecco’s 
modified medium supplemented with 10 % fetal bovine 
serum at 37 °C under 5 % CO2. For protein extraction, the 
cell lines were cultured to 80 % confluence, and then har-
vested with 0.1 % trypsin and 0.2 % EDTA.
LSCC tumor sections
Patients
The studies were performed on a group of 40 patients, 35 
men (age 44–77) and 5 women (age 50–69), who under-
went total laryngectomy in the Department of Otolaryn-
gology and Clinical Oncology Chair and Clinic of Oto-
laryngology Collegium Medicum in Bydgoszcz, Nicolaus 
Copernicus University in Torun, Poland. According to 
histopathological examination, performed by two inde-
pendent pathologists, squamous cell carcinoma (SCC) was 
diagnosed in all patients. The tumor stage was determined 
according to the current TNM classification of the Interna-
tional Union Against Cancer (IUAC) as follows: pT2—1 
case, pT3—27 cases, pT4—12 cases; pN0—20 cases, 
pN(+)—20 cases. No distant metastases (beyond loco-
regional lymph nodes) were found in the analyzed groups.
Material
The immunohistochemical studies were performed on 
selected archival formalin fixed paraffin embedded tis-
sue sections, which contain a representative area of squa-
mous cell carcinoma, derived from Department of Clinical 
Pathology, Collegium Medicum in Bydgoszcz, Nicolaus 
Copernicus University in Torun (Poland). All cases were 
revised and selected, according to HE stained tissue sec-
tions, by two independent pathologists. In each sample, 
cancer cells occupied approximately 80 % of tissue area, 
and the control sections contained a disease free normal 
mucosa, which were taken at least 2 cm away from the 
tumor resection margins.
The analyzed tissue material was divided into three 
groups: first group contained 20 tissue sections of pri-
mary LSCC from patients without lymph node metastases 
N(0), the second group contained 20 representative tis-
sue sections of primary LSCC from patients with lymph 
node metastases N(+) and the third group contained 20 
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representative tissue sections of lymph nodes containing 
SCC metastases.
Total protein isolation form LSCC cell lines
Cells were washed with PBS and then lysed in IEF buffer 
(7 M urea, 2 M thiourea, 2 % CHAPS 55 mM DTT and 
0.5 % v/v IPG buffer). Cell lysis was facilitated by sonication 
in three cycles. Insoluble material was removed by centrifu-
gation at 16 000g for 20 min. Protein concentration was esti-
mated using a commercial 2-D Quant kit (GE Healthcare).
2D protein electrophoresis
Protein separations and image analysis were carried out as 
previously described (Luczak et al. 2012). 24 cm IPG strips 
(pH 4-7, GE Healthcare) were actively rehydrated over-
night in IEF buffer containing cell samples. Each strip was 
loaded with the same amount of protein (650 µg). The strips 
were subjected to IEF on IPGphor III (GE Healthcare) 
using a ramping voltage (50–8000 V) to final 75,000 Vh. 
Second dimension was performed on 11 % polyacrylamide 
gels using the Ettan DALT six system (GE Healthcare). For 
each sample, a 2D analysis was repeated three times. After 
electrophoresis, gels were stained with Blue Silver over-
night (Candiano et al. 2004) and scanned with the Umax 
scanner (GE Healthcare) using LabScan program.
The images were analyzed using the Image Master Plati-
num software version 6.0 (GE Healthcare) and Progenesis 
SameSpots (Nonlinear Dynamics). The relative abundance 
of each spot (% vol) was calculated as its volume divided 
by the total volume of matched spots. To find differently 
accumulated proteins, gap and ratio measures were taken 
into account. For differentiating proteins threshold 1.5 was 
selected.
Analysis of variance between all groups was performed 
using the ANOVA test to check significant differences 
between the % volume of each spot in all groups of sam-
ples. The Mann–Whitney U test was performed to compare 
between two particular groups. P values <0.05 were con-
sidered statistically significant. All statistical analyses were 
performed using Statistica ver. 8.0 software.
In‑gel digestion
Individual protein spots were cut into small pieces, 
rinsed twice in 100 μL of washing buffer (50 mM 
NH4HCO3/100 % CH3CN (vol. 1:1)) for 15 min and dehy-
drated in 100 % CH3CN. The dried gel spots were rehy-
drated by the addition of 10 μL of digestion buffer [25 mM 
ammonium bicarbonate and 0.2 μg of sequencing-grade 
trypsin (Promega)]. Digestion was performed overnight at 
37 °C. Peptides were extracted with 10 % CH3CN.
Mass spectrometry
Proteins were identified using the MALDI-TOF/TOF 
mass spectrometer. The MALDI spectra were acquired 
on an UltrafleXtreme (Bruker Daltonics, Germany) mass 
spectrometer operated in reflector mode using delayed 
ion extraction. Positively charged ions in the m/z range of 
800–3500 were analyzed. For each sample, 0.5 µl was co-
crystallized with CHCA matrix and spotted directly onto the 
MALDI AnchorChip target (Bruker Daltonics, Germany). 
The MS spectra were externally calibrated using the Peptide 
Calibration Standard mixture (Bruker Daltonics, Germany). 
Flex control v. 3.3 was used for the acquisition of spectra, 
and all further data processing was performed using Flex 
analysis v. 3.3. Protein database searches using combined 
MS and MS/MS datasets were performed via BioTools 3.2 
(Bruker Daltonics, Germany). Proteins were identified using 
the Mascot (Matrix Science, London, UK) program against 
the SwissProt database (2012; 538 010 sequences in total). 
The false discovery rate (FDR) for peptide identification 
was 0.05 in all analyses. The protein search was performed 
using the following search parameters: precursor-ion mass 
tolerance, ±0.1 Da; fragment-ion mass tolerance, ±0.4 Da 
and cysteine-treated with iodoacetamide to form carbamido-
methyl-cysteine and oxidized methionine. Trypsin was set 
as the enzyme, with a maximum of one missed cleavage. 
Proteins were identified on the basis of at least two unique 
peptides with peptide score higher than 40 (p < 0.05). All 
analyses were done in triplicate.
The authors apologize and take the full responsibility for 
the missing peak lists and raw spectra of the analyzed pro-
teins. These raw data were lost and are not available any-
more. Instead, MALDI analyses in HTML format are avail-
able on request.
Immunohistochemistry
To determine the appropriate antibody dilution, eliminate 
false positive results, and reduce the background staining, 
a series of positive control reactions were performed on a 
model tissue selected according to antibody datasheets, and 
reference sources (The Human Protein Atlas: http://www.
proteinatlas.org (Uhlen et al. 2010). The positive control 
for selected antibodies is described in Table S2. Negative 
immunohistochemical control reactions were performed, 
by substituting the primary antibody with diluted 1 % 
BSA (bovine serum albumin) in PBS (phosphate buffered 
saline).
Selected paraffin blocks were cut using the manual 
rotary microtome (AccuCut, Sakura, Torrance, USA), to 
3.0 µm thick paraffin sections, placed on extra adhesive 
slides (SuperFrostPlus, MenzelGlasser, Braunschweig, 
Germany) and dried at 60 °C for 1 h.
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Deparaffinization, rehydration and antigen retrieval 
were performed automatically in high-pH antigen retrieval 
solution (cat. No K8004, Dako, Glostrup, Denmark) using 
PT-Link (Dako). Subsequently, sections were incubated 
for 10 min with 3 % H2O2, in room temperature to block 
the endogenous peroxidase, and furthermore, non-specific 
binding was blocked by incubation with 5 % BSA diluted 
in PBS for 10 min in room temperature. The detection of 
antigens was performed using primary mouse/rabbit mono-
clonal antibodies (Table S2). Then, the sections were incu-
bated for 20 min in 37 °C with peroxidase detection sys-
tem, Anti-Mouse/Anti-Rabbit EnVision Flex-HRP Labeled 
Polymer (cat. No K8000, Dako), and with DAB (3-3′diam-
inobenzidine) as a chromogen. Finally, the sections were 
counterstained with hematoxylin, dehydrated in increas-
ing ethanol concentrations (80, 90, 96, 99.8 %), cleared in 
xylenes (I–IV), and mounted with Shandon Consul Mount 
(Thermo Scientific, Waltham, USA).
Immunohistochemical analysis of protein abundance
The evaluation of protein abundance was performed in 
three hot spots (the tumor area with the highest immu-
nostaining), in the light microscope ECLIPSE E800 (Nikon 
Instruments Europe, Amsterdam, Netherlands) under 20× 
original objective magnification, equipped with cooled CD 
camera (Nikon Digital Sight DS-5Mc; Germany) driven by 
NIS Elements F 3.0 software (Nikon; Germany).
The level of selected protein abundance was evalu-
ated using Remmele–Stegner scale (Remmele and Steg-
ner 1987). Using the IRS scoring system, the percentage 
of positive stained cells/area (PP) and the intensity of the 
color reaction (SI) were taken into account. The final pro-
tein abundance (IRS = SI × PP) was presented as the ratio 
of the positively stained cells/area (PP) (scale 0–3; 0 = no 
staining, 1 <10 % stained cells/area; 2 = 10–50 % stained 
cells/area; 3 ≥50 % stained cells/area), and the intensity 
of protein abundance (SI) (scale 0–3; 0—no protein, 1—
weak; 2—moderate; 3—strong abundance).
All calculations were performed using STATISTICA 10 
(StatSoft). Normal distribution was tested using the Kol-
mogorov–Smirnov test with Lilliefors correction and the 
Shapiro–Wilk test and the variance was assessed using Lev-
ene’s test. For the statistical analysis U Mann–Whitney non-
parametric test was used, and p < 0.05 was considered as 
statistically significant.
Results
2D comparative proteome profiling of LSCC cell 
lines derived from primary tumors, recurrences 
and metastases
Total protein extracts from 26 LSCC cell lines were sub-
jected to 2D comparative proteome profiling. The cell lines 
Table 1  Short characteristic of the proteins showing different abundance between primary, recurrent tumors and metastases (2D comparative 
proteome profiling)
Fold change <1 means downregulation; significant differences are bolded










Theoretical pI Fold change (com-
pared to primary 
tumors)
Recurrent Metastases
1 Annexin V ANXA5_
HUMAN
51 163 16 35.9 4.94 0.83 1.63
2 Annexin III ANXA3_
HUMAN
30 108 10 36.5 5.63 0.42 0.50
3 Calreticulin CALR_
HUMAN
51 172 19 48.2 4.29 0.95 1.74




49 177 28 61.1 5.7 0.72 0.54
5 Heat shock 
















52 161 12 33 5.54 1.02 2.10
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were divided into three groups—derived from primary 
tumors (n = 11), recurrent tumors (n = 9) and metastases 
(n = 6). The proteome profiles between individual cell lines 
in the respective groups reveal some level of heterogeneity 
but the differences in number of protein spots detected in 
a cell line does not exceed 20 %. Moreover, no significant 
differences in the number of protein spots were observed 
between the analyzed groups.
After electrophoresis proteins were extracted from the 
gel and examined by MALDI-TOF/TOF mass spectrom-
etry. As a result, 122 proteins were identified. For all identi-
fied proteins the relative levels of their abundance in each 
sample were determined (mean from three analyses).
Seven protein spots showed recurrent and significant 
differences in relative abundance between the three ana-
lyzed groups. These spots were identified as the following 
proteins: Annexin III (ANXA3), Annexin V (ANXA5), 
calreticulin (CALR), heat shock protein 60 (HSP60), heat 
shock 70 kDa protein 9B (HSP70), inorganic pyrophos-
phatase (PPA1) and protein disulphide isomerase (PDIA3). 
Three of these proteins, namely HSP60 (p = 0.0097; 
p = 0.0019), HSP70 (p = 0.0074; p = 0.0011) and 
ANXA3 (p = 0.00065; p = 0.0011) were significantly 
downregulated both in the groups of recurrent tumors 
as well as metastases as compared to the group of pri-
mary tumors, respectively, and were not further studied. 
Whereas, ANXA5 (p = 0.025), CALR (p = 0.0019) and 
PPA1 (p = 0.0031) showed significant upregulation and 
PDIA3 (p = 0.00092) downregulation only in the group 
of metastases as compared to the group of primary tumors 
(Table 1; Fig. 1).
In summary, elevated levels of ANXA5, CALR and 
PPA1 proteins were identified as potential markers of 
metastases.
Immunohistochemical validation of ANXA5, CALR 
and PPA1 abundance in laryngeal squamous cell 
carcinoma
To validate the differential abundance of the three meta-
static marker candidates and to analyze their subcellular 
localization the immunohistochemical staining (IHC) was 
performed on 40 primary LSCC tissue sections including 
20 N(0), 20 N(+) cases, and 20 metastases of squamous 
cell carcinoma in lymph nodes [derived from the N(+) 
patients].
The analyses revealed membrane-cytoplasmatic abun-
dance of ANXA5 protein. The ANXA5 protein was found 
in 95 % cases of N(0) LSCC, in 75 % cases of N(+) LSCC, 
and in 70 % cases of meta SCC in lymph nodes. The mean 
percentage of positive cells in given cases was 8 % in N(0), 
6.6 % in N(+) and 8.8 % in metastatic tumors and the total 
IRS score was 2.1, 1.7 and 1.9, respectively. No signifi-
cant differences in abundance of the studied protein were 
observed in the analyzed groups.
Similarly, the CALR protein was observed in the cyto-
plasm and membrane. We observed much higher percent-
age of positive cells in the N(+) group (79 %) and the met-
astatic tumors (44 %) compared to the N(0) group (37 %). 
However, the total IRS scale was similar in all studied 
groups: IRS = 4 for N(0), IRS = 3.5 for N(+) and IRS = 4 
for the metastatic tumors. Moreover, no statistical differ-
ences of CALR abundance were observed among the three 
groups.
In contrast to the two above-mentioned proteins, PPA1 
showed cytoplasmatic and nuclear localization with abundant 




























Fig. 1  a Representative example of the 2D PAGE analysis of primary 
tumor cell line. IEF was performed in pH 4–7. The proteins show-
ing different abundance identified by mass spectrometry are indexed 
by numbers and boxed (see Table 1). b Examples of differentially 
expressed proteins
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positive cells (>90 %) in all three groups. Interestingly, we 
observed a shift in the fraction of cells showing combined 
nuclear and cytoplasmic staining [26.3 % of cells in N(0)] 
towards cells with cytoplasmic staining only [9.5 and 5.6 % 
cells with nuclear and cytoplasmic staining in N(+) and meta-
static tumors, respectively]. The deprivation of cells showing 
both, PPA1 cytoplasmatic and nuclear staining in N(+) and 
metastatic tumors is reflected in the IRS score for nuclear stain-
ing that fell from three in the N(0) group to two in the N(+) 
and the metastatic tumor groups. Importantly, our results show 
a significant increase of cytoplasmic PPA1 abundance in the 
N(+) (IRS = 6) and metastatic tumors (IRS = 6) compared 
to the N(0) group (IRS = 3). Moreover, the statistically sig-
nificant difference was observed between the PPA1 N(0) abun-
dance, and PPA1 N(+) abundance (p = 0.000042) (Fig. 2).
According to the above presented results the increase 
of PPA1 protein abundance but not of ANXA5 and CALR 
proteins is correlated with metastasis formation. Therefore, 
the PPA1 protein is an interesting novel marker candidate 
of metastasis.
Discussion
In this study, we aimed at the identification of differen-
tial proteins in primary tumors compared to recurrences/
metastases of LSCC. Using an approach that combines a 
2D electrophoresis-based protein screen in LSCC cell lines 
and subsequent immunohistochemical analysis of the can-
didate proteins in primary laryngeal cancer specimens, we 
identified the PPA1 protein that could possibly become a 
new marker for metastasis in this cancer.
The inorganic pyrophosphatase PPA1, member of the 
inorganic pyrophosphatase (PPase) family, is significantly 
up-regulated in LSCC cell lines derived from metastases 
compared to these derived from primary tumors. Impor-
tantly, we observed the same effect in immunohistochemi-
cally stained sections of primary LSCC tumors where 
sections derived from N(+) and metastases showed a sig-
nificantly more intensive staining than sections derived from 
N(0) tumors demonstrating that the differences in cell lines 
are not merely a side effect of cell culturing. There was also 
a shift in PPA1 staining from a mixed nuclear-cytoplasmic 
in N(0) tumors to cytoplasmic in LSCC metastases.
In vivo PPA1 functions in the regulation of cell cycle. 
Hyperphosphorylation of RB1 mediated by CDKs and its 
resulting inactivation is required for transition from the 
G1 to S phase of the cell cycle (Weinberg 1995; Korenjak 
and Brehm 2005). In contrast, the PPA1 protein regulates 
RB1 dephosphorylation leading to cell cycle arrest in the 
G1 phase and growth inhibition (Berndt et al. 1997). The 
tumor suppressive function of PPA1 presented above seems 
Fig. 2  a The immunohistochemical staining of PPA1 in normal 
mucosa and laryngeal squamous cell carcinoma. Positive nuclear-
cytoplasmic staining (brown), primary objective magnification ×10. 
b Median immunostaining of analyzed antigen in primary tumors, 
relative to lymph node involvement [N(0) vs. N(+)], and metastases 
in lymph nodes. IRS immunoreactive score
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contradictory to the observed elevated levels of the protein in 
the N(+) tumors. However, Berndt et al. demonstrated that 
the suppressive function of PPA1 requires the presence of 
wild type RB1 protein (Berndt et al. 1997) whereas deletions 
of the RB1 gene is a common phenomenon in squamous cell 
carcinoma of the head and neck. In our manuscript from 2002 
we have shown deletions of the RB1 gene in as much as 37 % 
of primary and 60 % of metastatic LSCC tumors (Kujawski 
et al. 2002). In light of these findings, the elevated levels of 
the PPA1 protein together with the shift from mixed cyto-
plasmic-nuclear staining to cytoplasmic staining in the N(+) 
tumors might therefore reflect a process of PPA1 accumula-
tion as consequence of aberrant RB1 suppressive pathway.
In addition, we show here decreasing abundance of the 
heat shock proteins HSP60 and HSP70 in cell lines derived 
from N(+) and metastases. This is intriguing, as it has been 
shown that heat shock proteins including HSP90 but also 
HSP70 protect mutated TP53 from degradation (Li et al. 
2011). Together, the TP53-heat shock protein complex 
presents a dominant negative function in tumor cells. The 
observed up-regulation of heat shock proteins together with 
frequent TP53 mutations might result in selection advan-
tage for cells in the primary LSCC tumors. This advantage 
might be no longer crucial in the recurrent or metastatic 
tumors that acquired additional genetic alterations.
In summary, we present here recurrent deregulations 
of Annexin III (ANXA3), Annexin V (ANXA5), calreti-
culin (CALR), heat shock protein 60 (HSP60), heat shock 
70 kDa protein 9B (HSP70), inorganic pyrophosphatase 
(PPA1) and protein disulphide isomerase (PDIA3) in LSCC 
cell lines. Moreover, we show elevated PPA1 protein lev-
els in the cytoplasm of N(+) LSCC tumors as compared 
to N(0) tumors. Therefore, the PPA1 protein is a potential 
marker candidate of metastasis in these tumors that could 
became useful in clinical routine examinations in the fol-
low-up schedule.
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